Status:
RECRUITING
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
Lead Sponsor:
French Africa Pediatric Oncology Group
Conditions:
Retinoblastoma
Eligibility:
All Genders
Up to 18 years
Brief Summary
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by i...
Detailed Description
In this study we will try to improve the outcome for children with stage II disease. It is hoped that we will be able to show that with early intervention correct early diagnosis the survival of these...
Eligibility Criteria
Inclusion
- Unilateral intraocular Retinoblastoma (RB)
- Unilateral extraocular intraorbital (RB)
- Bilateral intraocular (RB)
- bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.
Exclusion
- Externalized tumor mass
- massive extension to optic nerve up to optical channeltumor
- intracranial extension leptomeninges
- cerebral parenchyma
- extension to regional lymph nodes and/or remote metastases.
- cerebrospinal fluid involvement.
- Trilateral RB
- Incapacity to followed the whole treatement.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04425434
Start Date
November 1 2020
End Date
October 1 2029
Last Update
October 3 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Yalgado Ouedraogo
Ouagadougou, Burkina Faso, 03 BP 7022
2
CHU de Treichville à ABIDJAN
Abidjan, Côte d’Ivoire
3
CUK (Cliniques Universitaires de Kinshasa)
Kinshasa, Kinshasa City, Democratic Republic of the Congo, BP 12 KIN XI
4
Cliniques Universitaires de Lubumbashi (CUL)
Lubumbashi, Democratic Republic of the Congo, BP 1825